Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Aclaris Therapeutics reports Q1 results this morning with options traders running their most defensive positioning of the past year — even as the analyst community has rarely been more constructive on the stock.
The options market is the sharpest signal heading into the print. The put/call ratio has climbed to 0.59, its highest reading in 52 weeks, and nearly 2.6 standard deviations above its 20-day average of 0.40. That gap between current positioning and the recent baseline is unusually wide. It follows a session on Tuesday where the stock rose, yet downside protection demand accelerated — a pattern that typically reflects pre-earnings hedging rather than directional conviction. The stock has pulled back 4.5% in the most recent session and is down 3.5% on the week, trading at $4.42.
The analyst setup could hardly be more bullish by contrast. LifeSci Capital initiated coverage with an Outperform rating and a $13 target just yesterday — the fourth new or raised positive action in the past five weeks. Piper Sandler raised its target from $7 to $11 in early May; Guggenheim initiated at Buy with a $12 target on the same day. Nine analysts carry buy-equivalent ratings, with a mean price target of $10.00 — more than 125% above the current price. Bulls point to three potential blockbuster-plus pipeline opportunities: ATI-2138 for lichen planus, ATI-9494 approaching IND, and the TSLP/IL-4Ra bispecific ATI-052 in ongoing Phase 1b studies. Bears counter that pipeline execution has lagged, with PK/PD data for ATI-052 showing a shorter half-life than expected and competitive pressure from larger players making the ITK pathway more crowded than the bull case implies.
Short interest, meanwhile, is a secondary story rather than a primary one. At 7.0% of the free float — up around 1.9% in the last session but down 3.6% on the week — the short position is real but not aggressive. Borrow availability is extremely loose at over 3,100% of short interest, meaning the lending pool is deep and there is no mechanical squeeze pressure. Cost to borrow has risen sharply in recent weeks, from below 0.4% in mid-May to 1.6%, though it remains low in absolute terms. The ORTEX short score of 44.5 is mid-range and broadly stable. Institutional ownership shows notable fresh buying: Deep Track Capital, RA Capital, and Balyasny all entered or expanded positions in Q1, while BML — a 10% owner — trimmed by 300,000 shares in late April.
Past earnings prints have been punishing. The three most recent confirmed post-earnings moves show losses of 11.2%, 2.6%, and 13.3% on the day, with one outlier gain of 3.1% in May. The average five-day drift after those sessions has also been negative. The Q1 report is therefore less about the balance sheet and more about whether pipeline data — particularly any update on ATI-052 or ATI-2138 — can narrow the gap between the analyst community's optimism and the market's persistent caution.
See the live data behind this article on ORTEX.
Open ACRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
